Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23771163 | 0.80 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4ALDH1A1 | |
| SCHEMBL23771204 | 0.80 | LMNA (0.41) | CHRNB2CHRNA4CHRNB4ALDH1A1 | |
| SCHEMBL24568579 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4ALDH1A1CHRNA3 | |
| SCHEMBL24568580 | 0.80 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4ALDH1A1CHRNA3 | |
| SCHEMBL26416348 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16291989 | 0.78 | ALDH1A1 (0.48) | CHRNB2CHRNA4CHRNB4ALDH1A1 | |
| SCHEMBL1615800 | 0.77 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4ALDH1A1CHRNA3 | |
| SCHEMBL801270 | 0.74 | — | — | |
| SCHEMBL23771196 | 0.73 | MEN1 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1615790 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ADVANCION CORPORATION | 2023-04-27 | — | — | US | disclosed |
| WO-2021163348-A2 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ANGUS CHEMICAL COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | NME4, NMBR, NMUR1 | CHRNB2 253/4885CHRNA4 576/4885CHRNB4 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.